Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Clinical Guidelines Recommend NAFLD Screening for Obese Children

XTALKS VITALS NEWS

NAFLD

Though not necessarily damaging to health on its own, NAFLD can progress into nonalcoholic steatohepatitis (NASH), causing inflammation and serious scarring of the liver tissue.

Share this!

December 7, 2016 | by Sarah Hand, M.Sc.

New clinical practice guidelines developed by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), suggest that obese children between the ages of nine and 11 should be screened for non-alcoholic fatty liver disease (NAFLD). The guidelines were set forth in a paper published in the Journal of Pediatric Gastroenterology and Nutrition.

NAFLD is characterized by the accumulation of excess fat in the liver. The condition most often occurs in individuals who are overweight and have high cholesterol, though some people develop NAFLD without exhibiting any of the known risk factors.

Though not necessarily damaging to health on its own, NAFLD can progress into nonalcoholic steatohepatitis (NASH), causing inflammation and serious scarring of the liver tissue. This type of liver disease can even lead to cirrhosis, impacting the liver’s ability to function.



“[NAFLD] has rapidly evolved into the most common liver disease seen in the pediatric population and is a management challenge for the general pediatric practitioners, subspecialists, and health systems,” Dr. Miriam B. Vos of Emory University and Children’s Healthcare of Atlanta, and coworkers, write in the abstract for the paper. “In this guideline, the expert committee on NAFLD (ECON) reviewed and summarized the available literature, formulating recommendations to guide screening and clinical care of children with NAFLD.”

Recent research suggests that 0.7 percent of children aged two to four may have NAFLD, with that number jumping up to 38 percent of obese children and young adults. NAFLD has also surpassed other liver diseases as the most common cause of liver transplants in adult patients.

The NASPGHAN guidelines recommend that obese children are screened for NAFLD using an alanine aminotransferase (ALT) liver enzyme test. A liver biopsy may be needed to confirm a diagnosis, and lifestyle changes – such as a healthier diet and more physical activity – are the recommended treatment options for NAFLD.

These new guidelines have also been endorsed by the American Academy of Pediatrics. The hope is that these clinical guidelines will help physicians diagnose and manage NAFLD in pediatric patients, using evidence-based approaches and screening methods.


Keywords: NAFLD, Obesity, Pediatric Health


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.